Stocks · News reference
Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Hims & Hers Health, Inc. and Eli Lilly and Company have entered into an agreement to provide patients on the Hims & Hers platform access to Lilly's obesity medications, Zepbound and Foundayo.
Eli Lilly and Company has reached an agreement with Hims & Hers to provide patients with direct access to its FDA-approved obesity medications, Zepbound and Foundayo, through the Hims & Hers platform.
BofA Securities analyst Jason Gerberry maintained a 'Buy' rating on Eli Lilly and Company while increasing the price target from $1,497 to $1,557.
Zenith Epigenetics has executed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to study the combination of ZEN-3694 and Verzenio in patients with NUT carcinoma.